非ホジキンリンパ腫(NHL)の疫学的予測(~2024)

◆英語タイトル:EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
◆商品コード:GDHCER113-15
◆発行会社(リサーチ会社):GlobalData
◆発行日:2016年1月1日
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥451,435見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥902,870見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,354,305見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、非ホジキンリンパ腫(NHL)の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・非ホジキンリンパ腫(NHL)の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・非ホジキンリンパ腫(NHL)の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Non-Hodgkin’s Lymphoma – Epidemiology Forecast to 2024

Summary

Non-Hodgkin’s Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight infections and other diseases. NHL is characterized into three types – B-cell, T-cell, and natural killer lymphocyte lymphomas. This epidemiological analysis focuses specifically on four subtypes of B-cell NHL: follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma. NHL is more common in men than in women, in white men and women compared with black men and women, and the incidence exponentially increases with age.

GlobalData epidemiologists forecast an increase in the incident cases of the four B-cell NHL in the 7MM, from 104,854 incident cases in 2014 to 129,179 incident cases in 2024, with an annual growth rate (AGR) of 2.32%. Throughout the forecast period, the US will have the highest number of incident cases of B-cell NHL, as well as 36% growth during the forecast period, ending with 57,724 incident cases in 2024. Additionally, each of the 7MM will see an increase in incident cases over the 10-year forecast period.

For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and country-specific disease databases to construct the 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the 7MM. A major strength of GlobalData’s epidemiological analysis is the exclusive use of country-specific sources, allowing for a meaningful comparison of the epidemiological characteristics of B-cell NHL in the 7MM. In addition, this forecast provides detailed segmentation of the B-cell NHL for each country by age, sex, and B-cell NHL subtype, thereby providing a comprehensive view of B-cell NHL in the seven markets. Furthermore, GlobalData epidemiologists constructed and analyzed each B-cell NHL subtype individually, which facilitated an in-depth understanding of B-cell NHL in the 7MM.

Scope

- The Non-Hodgkin’s Lymphoma (NHL) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for NHL in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the incident cases of NHL segmented by sex, age (in five-year increments beginning at 30 years and ending at =85 years), and subtypes in these markets.
- The NHL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The NHL EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global NHL market.
- Quantify patient populations in the global NHL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for NHL therapeutics in each of the markets covered.

【レポートの目次】

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 12
3.3.1 US 12
3.3.2 5EU 13
3.3.3 Japan 16
3.4 Forecast Methodology 16
3.4.1 Sources Used 19
3.4.2 Sources Not Used 22
3.4.3 Forecast Assumptions and Methods 23
3.5 Epidemiological Forecast for B-Cell NHL (2014-2024) 27
3.5.1 Follicular Lymphoma 27
3.5.2 Marginal Zone Lymphoma 35
3.5.3 DLBCL 42
3.5.4 Mantle Cell Lymphoma 49
3.6 Discussion 56
3.6.1 Epidemiological Forecast Insight 56
3.6.2 Limitations of the Analysis 56
3.6.3 Strengths of the Analysis 57
4 Appendix 58
4.1 Bibliography 58
4.2 About the Authors 62
4.2.1 Epidemiologists 62
4.2.2 Reviewers 63
4.2.3 Global Director of Therapy Analysis and Epidemiology 64
4.2.4 Global Head of Healthcare 64
4.3 About GlobalData 65
4.4 About EpiCast 65
4.5 Disclaimer 66

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for NHL 11
Table 2: US, Age- and Sex-Specific Incidence of B-Cell NHL during 2001-2010 13
Table 3: 7MM, Sources of B-Cell NHL Incidence Data 18
Table 4: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024 28
Table 5: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2014 30
Table 6: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N (Row %), 2014 32
Table 7: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024 35
Table 8: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2014 37
Table 9: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N (Row %), 2014 39
Table 10: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024 42
Table 11: 7MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2014 44
Table 12: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N (Row %), 2014 46
Table 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024 49
Table 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2014 51
Table 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N (Row %), 2014 53

1.2 List of Figures
Figure 1: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024 28
Figure 2: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014 31
Figure 3: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N, 2014 33
Figure 4: 7MM, Age-Standardized Incidence of Follicular Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014 34
Figure 5: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024 36
Figure 6: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014 38
Figure 7: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N, 2014 40
Figure 8: 7MM, Age-Standardized Incidence of Marginal Zone Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014 41
Figure 9: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014-2024 43
Figure 10: 7MM, Age-Specific Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014 45
Figure 11: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N, 2014 47
Figure 12: 7MM, Age-Standardized Incidence of DLBCL (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014 48
Figure 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024 50
Figure 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N, 2014 52
Figure 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N, 2014 54
Figure 16: 7MM, Age-Standardized Incidence of Mantle Cell Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014 55

【レポートのキーワード】

非ホジキンリンパ腫(NHL)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[非ホジキンリンパ腫(NHL)の疫学的予測(~2024)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆